1606 Corp. supports Adnexus AI health tech; LOI terminated but still pursuing deal

1606 CORP.

1606 Corp. issued press release supporting Adnexus Biotechnologies' Neural Temporal Fingerprinting AI technology for personalized health monitoring using EEG/ECG.
Adnexus' technology targets early detection of Alzheimer's, Parkinson's, PTSD, and cardiovascular risks via AI analysis of EEG/ECG signals.
Previously signed LOI for strategic investment by 1606 in Adnexus terminated on Nov 28, 2024, but parties still working to close the deal.
CEO Austen Lambrecht sees transformative potential in AI-driven health diagnostics and wearable integration for both companies.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.